{
  "slug": "glucosamine",
  "name": "Glucosamine / Chondroitin",
  "alternate_names": [
    "Glucosamine Sulfate",
    "Glucosamine HCl",
    "Crystalline Glucosamine Sulfate (pCGS)",
    "Chondroitin Sulfate",
    "Glucosamine-Chondroitin Combination"
  ],
  "mechanism": [
    "Substrate precursor for glycosaminoglycan / proteoglycan synthesis in articular cartilage (research-described)",
    "Hexosamine pathway flux modulation (mechanistic, proposed link to anti-inflammatory and low-carb-mimetic signaling)",
    "NF-kB signaling inhibition (preclinical / mechanistic)",
    "COX-2 expression and PGE2 down-regulation (preclinical / mechanistic)",
    "Associated with lower circulating CRP in cohort data (observational, not causal)"
  ],
  "target": [
    "Articular cartilage / proteoglycan matrix",
    "NF-kB pathway",
    "COX-2 / PGE2",
    "IL-6 / CRP (inflammatory markers, observational)"
  ],
  "use_case": [
    "studied for knee osteoarthritis symptom support (pain, stiffness, function) — strongest evidence with crystalline glucosamine sulfate",
    "researched for joint structure / cartilage maintenance (joint-space-narrowing endpoints, mixed)",
    "explored for inflammatory-marker (CRP) modulation (RCT + cohort, mixed)",
    "observed association with lower all-cause and cardiovascular mortality in large cohorts (observational only — NOT a causal or longevity claim)"
  ],
  "body_system": [
    "MUSCULO",
    "CARDIO",
    "IMMUNE",
    "GUT"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 4,
  "dosage_range": "1500 mg/day glucosamine (single or 3 divided doses), often combined with 1200 mg/day chondroitin sulfate. Clinical onset is slow (4-8 weeks); structural-endpoint trials run 6-36 months. Strongest evidence is specifically for crystalline glucosamine SULFATE (pCGS) at 1500 mg/day; glucosamine HCl human data are weaker (the GAIT trial used HCl).",
  "safety_notes": "Generally well tolerated; in long-term RCTs (up to 3 years) adverse-event rates are comparable to placebo, most commonly mild GI upset (nausea, bloating, diarrhea). CRUSTACEAN ALLERGEN — HARD red line: most glucosamine is shellfish-derived (shrimp/crab shell) and must be labeled as crustacean-sourced; shellfish-allergic individuals should avoid unless a fermentation/corn-derived \"shellfish-free\" source is documented (FDA treats an undeclared crustacean allergen as a Class I recall). Warfarin: case reports of increased INR — anticoagulant users should be monitored. Glucose metabolism: early theoretical concern that glucosamine raises blood glucose has not been confirmed clinically in RCTs/SRs (Muniyappa 2006 PMID 17065354; Dostrovsky 2011 SR PMID 21251987), but diabetic-population labeling caution is retained. No adequate safety data in pregnancy, lactation, or children <18 — not recommended for these groups.",
  "regulatory": {
    "fda": "Dietary-supplement ingredient under DSHEA (pre-1994 'old' ingredient, no NDI needed); glucosamine HCl is GRAS; USP-NF monographs exist for glucosamine sulfate, glucosamine HCl, and chondroitin sulfate sodium. Structure/function claims only — disease (OA 'treatment') claims prohibited; mandatory FDA disclaimer required. Undeclared crustacean allergen = Class I recall (FALCPA).",
    "efsa": "EFSA REJECTED all Article 13 joint-health claims for glucosamine (evidence deemed insufficient for causality given heterogeneity of sulfate vs HCl, dose, and population) — NO authorized EU health claim as a food supplement. Separately, crystalline glucosamine sulfate (pCGS, Dona/Viartril-S) is a PRESCRIPTION SYSADOA drug in several EU states (IT/ES/PT/IE/GR) and is ESCEO-recommended as OA Step-1; prescription-drug evidence must NOT be cited to support supplement claims. Crustacean allergen labeling mandatory (Reg 1169/2011).",
    "anvisa": "Permitted dietary-supplement ingredient (Suplemento Alimentar). RDC 243/2018 framework; IN 28/2018 positive list. Limits: glucosamine <=1500 mg/day, chondroitin sulfate <=1200 mg/day. Portuguese labeling required; crustacean allergen must be labeled 'Contém derivados de crustáceos'. (China NMPA: health-food ingredient, approved function 'enhances bone mineral density'; NOT permitted in conventional foods; also marketed separately as an Rx OA drug.)"
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/glucosamine/",
  "related_goal_slugs": [
    "joint-bone"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}